A phase i study of 4′-0-tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics
✍ Scribed by Kasi S. Sridhar; T. S. Anantha Samy; Ram P. Agarwal; Robert C. Duncan; Pasquale Benedetto; Awtar G. Krishan; Charles L. Vogel; Lynn G. Feun; Niramol M. Savaraj; Stephen P. Richman; C. Gordon Zubrod
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 962 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r
## BACKGROUND. Compared with free drug, sterically stabilized liposomal drug has prolonged circulation time and, thereby, higher tumor selectivity and antitumor activity. The stability in plasma is an important consideration in the formulation of clinically useful liposomal drug. A Phase I study o